BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21276943)

  • 1. SHP2 is a target of the immunosuppressant tautomycetin.
    Liu S; Yu Z; Yu X; Huang SX; Luo Y; Wu L; Shen W; Yang Z; Wang L; Gunawan AM; Chan RJ; Shen B; Zhang ZY
    Chem Biol; 2011 Jan; 18(1):101-10. PubMed ID: 21276943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of demethylincisterol A
    Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
    Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
    Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
    Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2.
    Chen C; Cao M; Zhu S; Wang C; Liang F; Yan L; Luo D
    Sci Rep; 2015 Dec; 5():17626. PubMed ID: 26626996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
    Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
    Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
    Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF
    Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
    Zhang X; He Y; Liu S; Yu Z; Jiang ZX; Yang Z; Dong Y; Nabinger SC; Wu L; Gunawan AM; Wang L; Chan RJ; Zhang ZY
    J Med Chem; 2010 Mar; 53(6):2482-93. PubMed ID: 20170098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of scaffolding adaptor protein Gab1 with tyrosine phosphatase SHP2 negatively regulates IGF-I-dependent myogenic differentiation via the ERK1/2 signaling pathway.
    Koyama T; Nakaoka Y; Fujio Y; Hirota H; Nishida K; Sugiyama S; Okamoto K; Yamauchi-Takihara K; Yoshimura M; Mochizuki S; Hori M; Hirano T; Mochizuki N
    J Biol Chem; 2008 Aug; 283(35):24234-44. PubMed ID: 18577518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking.
    Hellmuth K; Grosskopf S; Lum CT; Würtele M; Röder N; von Kries JP; Rosario M; Rademann J; Birchmeier W
    Proc Natl Acad Sci U S A; 2008 May; 105(20):7275-80. PubMed ID: 18480264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the tautomycetin biosynthetic gene cluster from Streptomyces griseochromogenes provides new insight into dialkylmaleic anhydride biosynthesis.
    Li W; Luo Y; Ju J; Rajski SR; Osada H; Shen B
    J Nat Prod; 2009 Mar; 72(3):450-9. PubMed ID: 19191560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of targeting the oncogenic SHP2 phosphatase.
    Zeng LF; Zhang RY; Yu ZH; Li S; Wu L; Gunawan AM; Lane BS; Mali RS; Li X; Chan RJ; Kapur R; Wells CD; Zhang ZY
    J Med Chem; 2014 Aug; 57(15):6594-609. PubMed ID: 25003231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
    Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
    J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Shp2 with phosphorylated IL-22R1 is required for interleukin-22-induced MAP kinase activation.
    Meng S; Gui Q; Xu Q; Lu K; Jiao X; Fan J; Ge B; Ke Y; Zhang S; Wu J; Wang C
    J Mol Cell Biol; 2010 Aug; 2(4):223-30. PubMed ID: 20671117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).
    Liu W; Yu B; Xu G; Xu WR; Loh ML; Tang LD; Qu CK
    J Med Chem; 2013 Sep; 56(18):7212-21. PubMed ID: 23957426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).
    Hartman Z; Geldenhuys WJ; Agazie YM
    J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening.
    Yu ZH; Chen L; Wu L; Liu S; Wang L; Zhang ZY
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4238-42. PubMed ID: 21669525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase.
    Miura K; Wakayama Y; Tanino M; Orba Y; Sawa H; Hatakeyama M; Tanaka S; Sabe H; Mochizuki N
    Oncogene; 2013 Nov; 32(45):5292-301. PubMed ID: 23318428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2.
    Chio CM; Lim CS; Bishop AC
    Biochemistry; 2015 Jan; 54(2):497-504. PubMed ID: 25519989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
    Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
    Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.